Triad Wealth Partners LLC Invests $49,000 in GSK plc (NYSE:GSK)

Triad Wealth Partners LLC bought a new position in GSK plc (NYSE:GSK) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,264 shares of the pharmaceutical company’s stock, valued at approximately $49,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Abundance Wealth Counselors increased its position in GSK by 9.4% during the 2nd quarter. Abundance Wealth Counselors now owns 21,684 shares of the pharmaceutical company’s stock valued at $835,000 after purchasing an additional 1,868 shares during the period. Seed Wealth Management Inc. boosted its holdings in shares of GSK by 5.9% during the 2nd quarter. Seed Wealth Management Inc. now owns 7,520 shares of the pharmaceutical company’s stock worth $290,000 after buying an additional 420 shares in the last quarter. ORG Partners LLC boosted its holdings in shares of GSK by 663.5% during the 2nd quarter. ORG Partners LLC now owns 1,611 shares of the pharmaceutical company’s stock worth $62,000 after buying an additional 1,400 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of GSK by 5.6% during the 2nd quarter. V Square Quantitative Management LLC now owns 16,127 shares of the pharmaceutical company’s stock worth $623,000 after buying an additional 853 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its holdings in shares of GSK by 5.7% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 166,255 shares of the pharmaceutical company’s stock worth $6,401,000 after buying an additional 8,989 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on GSK shares. Berenberg Bank upgraded GSK to a “strong-buy” rating in a report on Thursday, June 20th. The Goldman Sachs Group started coverage on GSK in a report on Thursday, May 30th. They set a “neutral” rating and a $47.00 price target on the stock. Jefferies Financial Group increased their price target on GSK from $52.50 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Finally, Citigroup upgraded GSK to a “strong-buy” rating in a report on Monday, June 24th. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $50.00.

GSK Stock Down 0.3 %

NYSE:GSK traded down $0.11 during trading hours on Friday, hitting $41.29. 3,145,741 shares of the company traded hands, compared to its average volume of 3,581,986. The company has a quick ratio of 0.58, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. The firm’s 50-day simple moving average is $39.73 and its 200-day simple moving average is $41.46. GSK plc has a one year low of $33.67 and a one year high of $45.92. The company has a market cap of $85.57 billion, a PE ratio of 14.96, a PEG ratio of 1.32 and a beta of 0.64.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Stockholders of record on Friday, August 16th will be given a dividend of $0.3843 per share. The ex-dividend date of this dividend is Friday, August 16th. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 annualized dividend and a dividend yield of 3.72%. GSK’s dividend payout ratio (DPR) is currently 54.71%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.